MX2022009987A - Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. - Google Patents

Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.

Info

Publication number
MX2022009987A
MX2022009987A MX2022009987A MX2022009987A MX2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A MX 2022009987 A MX2022009987 A MX 2022009987A
Authority
MX
Mexico
Prior art keywords
ulcerative colitis
antibody
safe
effective method
treating ulcerative
Prior art date
Application number
MX2022009987A
Other languages
English (en)
Spanish (es)
Inventor
Omoniyi Adedokun
Jewel Johanns
Katherine Li
Colleen Marano
Richard Strauss
Hongyan Zhang
Kimberly Shields-Tuttle
Christopher O''BRIEN
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022009987A publication Critical patent/MX2022009987A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2022009987A 2020-02-14 2021-02-12 Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23. MX2022009987A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976582P 2020-02-14 2020-02-14
PCT/IB2021/051215 WO2021161270A2 (en) 2020-02-14 2021-02-12 Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody

Publications (1)

Publication Number Publication Date
MX2022009987A true MX2022009987A (es) 2022-11-10

Family

ID=77271772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009987A MX2022009987A (es) 2020-02-14 2021-02-12 Método seguro y efectivo para tratar la colitis ulcerosa con el anticuerpo anti-il-12/il23.

Country Status (11)

Country Link
US (2) US20210253690A1 (enExample)
EP (1) EP4103606A4 (enExample)
JP (2) JP2023514567A (enExample)
KR (1) KR20220141847A (enExample)
CN (1) CN115427444A (enExample)
AU (1) AU2021218265A1 (enExample)
BR (1) BR112022015996A2 (enExample)
CA (1) CA3170677A1 (enExample)
IL (1) IL295545A (enExample)
MX (1) MX2022009987A (enExample)
WO (1) WO2021161270A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024151320A2 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205276A4 (en) * 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
US20170211876A1 (en) * 2014-06-12 2017-07-27 Hoffmann-La Roche Inc. Method for selecting antibodies with modified fcrn interaction
MX2018003376A (es) * 2015-09-17 2018-08-15 Amgen Inc Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗il12/il23抗體治療狼瘡之安全且有效之方法
TWI744617B (zh) * 2018-03-30 2021-11-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法

Also Published As

Publication number Publication date
BR112022015996A2 (pt) 2022-10-11
EP4103606A2 (en) 2022-12-21
CA3170677A1 (en) 2021-08-19
CN115427444A (zh) 2022-12-02
WO2021161270A2 (en) 2021-08-19
IL295545A (en) 2022-10-01
KR20220141847A (ko) 2022-10-20
EP4103606A4 (en) 2024-04-10
WO2021161270A3 (en) 2021-09-16
JP2023514567A (ja) 2023-04-06
WO2021161270A9 (en) 2022-03-24
JP2026097829A (ja) 2026-06-16
US20240002494A1 (en) 2024-01-04
AU2021218265A1 (en) 2022-10-06
US20210253690A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
MX2021003411A (es) Metodo seguro y eficaz para tratar la colitis ulcerosa con el anticuerpo anti-il12/il23.
EP4233861A3 (en) Compositions for treatment of essential tremor
WO2021161270A9 (en) Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
EP1692516A4 (en) THERAPY PROCESS
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2022195074A3 (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
MX2022013923A (es) Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
PH12021553055A1 (en) Methods and compositions for improving outcomes of cancer patients
MX2023004017A (es) Método para tratar la enfermedad de crohn con anticuerpo anti-il12/il23.
EP4424381A3 (en) Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
WO2017123667A3 (en) Non-ischemic heart failure treatment by cell therapy
ZA202211308B (en) Endoxifen for the treatment of bipolar i disorder
PH12022553441A1 (en) Compositions and methods for treating obsessive-compulsive disorder
MX2024005197A (es) Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23.
MX2023008876A (es) Tratamiento de la apnea del sueño con cannabidiol (cbd).
Zhang et al. Intraoperative tumor lysis-induced fatal hyperkalemia
EA032959B9 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
Wood New local therapy strategies for brain tumours
RU2010107158A (ru) Способ лечения экомодифицированного атопического дерматита у детей, проживающих в условиях воздействия техногенных химических факторов
YUAN et al. CLINICAL APPLICATION EXPERIENCE OF KAIHE LIUQI ACUPUNCTURE METHOD FOR TREATING NECK, SHOULDER AND BACK PAIN DISEASES
MX2024008256A (es) Metodos de tratamiento de la enfermedad por coronavirus y compuestos para el mismo.
MX2024005860A (es) Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23.
EA202190858A1 (ru) Безопасный и эффективный способ лечения язвенного колита с помощью антител к il-12/il-23
Gu et al. " Tongdu Yisui" acupuncture and moxibustion for 15 cases of Meige syndrome